Home Hidradenitis Suppurativa Dr. Alice Gottlieb Presents HS Bermekimab Findings at AADAM

Dr. Alice Gottlieb Presents HS Bermekimab Findings at AADAM

300
0

XBiotech reports that Scientific Board member Dr. Alice Gottlieb will present “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurative HS, Including Marked Reduction in Pain” during the afternoon session on March 2nd, 2019 at the American Academy of Dermatology Annual Meeting held at the Walter E. Washington Convention Center in Washington D.C. The presentation, accepted as “late-breaking research: clinical trials” will provide details of the Company’s recent phase II clinical trial results in 42 HS patients that received 400mg subcutaneous weekly doses of bermekimab in a 12-week treatment regimen.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.